The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action
On August 1, 2010, a revised guidance regarding bioequivalence (BE) assessment for the approval of innovator (bridging studies, variations, line extensions) and generic medicinal products in the EU came into effect. This revised guideline specifies the requirements for BE assessment for immediate re...
Main Authors: | Roger K Verbeeck, Flora T Musuamba |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2012-06-01
|
Series: | Journal of Pharmacy & Pharmaceutical Sciences |
Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/11759 |
Similar Items
-
Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development
by: Joseph Kotsybar, et al.
Published: (2023-12-01) -
Evaluation of Pharmacokinetics and Safety with Bioequivalence of Ibuprofen Sustained-Release Capsules of Two Formulations, in Chinese Healthy Volunteers: Bioequivalence Study
by: Huang C, et al.
Published: (2023-06-01) -
Pharmacokinetics and bioequivalence of two cyclosporine oral solution formulations in cats
by: Yuxin Yang, et al.
Published: (2022-08-01) -
Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs
by: Nakkawee Saengklub, et al.
Published: (2022-03-01) -
Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs
by: Muhammad M. Hammami, et al.
Published: (2017-12-01)